Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isavuconazonium - Basilea Pharmaceutica

Next Previous
X
Search
Drug Profile

Isavuconazonium - Basilea Pharmaceutica

Alternative Names: AK-1820; ASP-9766; BAL-8557; BAL-8557-000; BAL-8557-002; BAL-9557; Cresemba; Isavuconazole; Isavuconazonium chloride; Isavuconazonium sulfate; Isavuconazonium sulphate

Latest Information Update: 28 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; Avir Pharma; Basilea Pharmaceutica; Hikma Pharmaceuticals; Knight Therapeutics; Memorial Sloan-Kettering Cancer Center; Pfizer
  • Class Antifungals; Antineoplastics; Fluorinated hydrocarbons; Inorganic sulfur compounds; Nitriles; Pyridines; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive candidiasis; Invasive bronchopulmonary aspergillosis; Zygomycosis; Candidaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Invasive bronchopulmonary aspergillosis; Mycoses; Zygomycosis
  • Phase III Candidiasis
  • No development reported Haematological malignancies

Most Recent Events

  • 27 Aug 2024 Launched for Invasive bronchopulmonary aspergillosis (In adolescents, In children, In infants) in European Union (IV)
  • 27 Aug 2024 Launched for Invasive bronchopulmonary aspergillosis (In adolescents, In children, In infants) in European Union (PO)
  • 27 Aug 2024 Launched for Invasive bronchopulmonary aspergillosis (In adolescents, In children, In infants) in Iceland, Liechtenstein, Norway (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top